Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Akeso has dosed the first patient in a Phase Ib/II study evaluating the HER3 antibody-drug conjugate AK138D1 with ivonescimab in advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC

Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.

Read More
ViiV Healthcare’s two-drug Dovato regimen matched the three-drug Biktarvy regimen for viral suppression at Week 48 in the head-to-head VOGUE HIV study. Representative image.
Pharma & Biotech

ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data

ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.

Read More
A clinical research setting illustrates Arrowhead Pharmaceuticals’ Phase 3 YOSEMITE trial evaluating zodasiran for homozygous familial hypercholesterolemia following completion of global patient enrollment. Representative image.
Pharma & Biotech

Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?

Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.

Read More
Otsuka’s VOYXACT Phase 3 VISIONARY trial is moving into a decisive stage as two-year eGFR results assess whether sibeprenlimab can preserve kidney function in adults with IgA nephropathy. Representative image.
Pharma & Biotech

Can VOYXACT move beyond proteinuria? Otsuka’s two-year VISIONARY data may decide its FDA future

Otsuka will unveil two-year VISIONARY eGFR data for VOYXACT, a pivotal test of kidney preservation and its path to full FDA approval.

Read More
Representative image: A clinician applies a microneedle skin patch as Medicus Pharma $MDCX advances its SkinJect treatment into an FDA-cleared Phase 2b study for basal cell carcinomas in Gorlin syndrome.
Pharma & Biotech

FDA clears Medicus Pharma SkinJect registrational study in Gorlin syndrome

FDA clears Medicus Pharma’s Phase 2b SkinJect study in Gorlin syndrome with biopsy-confirmed endpoints and two-year follow-up.

Read More
Representative image: A neurological research team reviews brain scans and antisense therapy data as CAMP4 Therapeutics $CAMP prepares to begin the first human CMP-002 trial for SYNGAP1-related disorder.
Pharma & Biotech

CAMP4 clears Australian hurdle for first human CMP-002 study in SYNGAP1 disorder

CAMP4 gains Australian clearance for a Phase 1/2 CMP-002 trial targeting the genetic cause of SYNGAP1-related disorder.

Read More
Massive Bio expands Latin America oncology strategy through GELL research partnership
Pharma & Biotech

Can Massive Bio and GELL turn Latin America’s lymphoma research gaps into an AI-powered clinical trial advantage?

Massive Bio and GELL unite on oncology research, education and AI, but execution will determine whether the alliance expands trial access.

Read More
Huonslab’s new patent targets subcutaneous antibody-drug conjugate formulations using its HyDIFFUZE platform, highlighting the growing race to make complex oncology therapies easier and faster to administer. Representative image.
Pharma & Biotech

Can Huonslab crack oncology’s next drug-delivery problem? New patent targets injectable ADCs

Huonslab’s HyDIFFUZE patent targets subcutaneous ADC formulations, but preclinical evidence and clinical translation remain the real test.

Read More
Precision BioSciences’ leadership reshuffle puts PBGENE-HBV and PBGENE-DMD clinical execution in focus as the gene-editing company approaches key 2026 milestones. Representative image.
Pharma & Biotech

Precision BioSciences prepares leadership team for PBGENE-HBV and PBGENE-DMD data milestones

Precision BioSciences reshapes leadership to support PBGENE-HBV and PBGENE-DMD as two gene-editing trials approach key 2026 milestones.

Read More
Vasomune Therapeutics is positioning investigational Tie2 agonist Pegevongitide for potential use in vascular leak, severe trauma and CBRN-related medical emergencies ahead of its NATO NSPA presentation. Representative image.
Pharma & Biotech

Why Vasomune is taking its vascular leak drug to NATO before the clinical case is settled

Vasomune will present Pegevongitide at NATO’s CBRN forum, but clinical data and countermeasure readiness remain the decisive tests.

Read More